The burden of rheumatoid arthritis and access to treatment: Determinants of access

European Journal of Health Economics

Volumn 8, Issue SUPPL. 8, 2008, Pages

  Lundqvist, J ^a   Kastang F ^a   Kobelt, G ^b   Jonsson B ^c  

^a i3 Innovus   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Health technology assessment; Rheumatoid arthritis; Treatment access

Indexed keywords

ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC EVALUATION; HEALTH CARE ACCESS; HEALTH CARE COST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMEDICAL TECHNOLOGY; COST OF ILLNESS; DATABASES, FACTUAL; DRUG APPROVAL; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MARKETING OF HEALTH SERVICES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 38449089887     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0090-1     Document Type: Article

References (17)

1. Magnusson, S.: Treatment of rheumatoid arthritis-does it affect society's cost for the disease? Br. J. Rheumatol. 35, 791-795 (1996)
2. EFPIA (2002) The European Federation of Pharmaceutical Industries and Associations annual report. http://www.efpia.org/6_publ/annual/Report2002.pdf
3. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L.: Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107-142 (1991)
4. DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003)
5. Adams, C.P., Brantner, V.V.: Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25, 420-428 (2006)
6. Motola, D., De Ponti, F., Poluzzi, E., et al.: An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62, 610-616 (2006)
7. European Medicines Agency (EMEA). http://www.emea.eu.int
8. Anderson, C., McAuslane, N., Walker, S.: The impact of the changing regulatory environment on review times. CMR, International R&D briefing No.35 (online). http://www.cmr.org/pdf/r_d35.pdf (2002)
9. Health Canada (2005) Priority review of drug submissions. Guidance Date 30 11 2005
10. Food and Drug Administration (FDA) USA. http://www.fda.gov
11. Danzon, P.M., Furukawa, M.F.: Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) (Suppl) Web Exclus. W3:521-536 (2003)
12. Pharmaceutical Price Controls in OECD Countries (2004) Implications of U.S. Consumers, Pricing, Research and Development, and Innovation. U.S. Department of Commerce International Trade Administration, Washington, DC
13. Patients W.A.I.T. Indicator (2007) Phase 6 Report. IMS Management Consulting
14. National Institute for Clinical Excellence (2002) Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technol. Appraisal no. 36 (March)
15. Sundhedsstyrelsen Center for Evaluering og Medicinsk Teknologivurdering. Rheumatoid Arthritis (2002) Health Technology Assessment of diagnosis and treatment. Medicinsk Teknologivurdering 4
16. Coyle, D., Judd, M., Blumenauer, B., et al.: Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation (Technology report no 64). Canadian Coordinating Office for Health Technology Assessment, Ottawa (2006)
17. National Institute for Clinical Excellence (2003) Anakinra for rheumatoid arthritis. Technol. Appraisal 72 (November)